These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15388420)

  • 81. Design and evaluation of an in-house HIV-1 (group M and O), SIVmnd and SIVcpz antigen capture assay.
    Beirnaert E; Willems B; Peeters M; Bouckaert A; Heyndrickx L; Zhong P; Vereecken K; Coppens S; Davis D; Ndumbe P; Janssens W; van der Groen G
    J Virol Methods; 1998 Jul; 73(1):65-70. PubMed ID: 9705176
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.
    Carr A; Samaras K; Chisholm DJ; Cooper DA
    Lancet; 1998 Jun; 351(9119):1881-3. PubMed ID: 9652687
    [TBL] [Abstract][Full Text] [Related]  

  • 83. HIV-1 selection by epidermal dendritic cells during transmission across human skin.
    Reece JC; Handley AJ; Anstee EJ; Morrison WA; Crowe SM; Cameron PU
    J Exp Med; 1998 May; 187(10):1623-31. PubMed ID: 9584140
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
    Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM
    JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS
    Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques.
    Spira AI; Marx PA; Patterson BK; Mahoney J; Koup RA; Wolinsky SM; Ho DD
    J Exp Med; 1996 Jan; 183(1):215-25. PubMed ID: 8551225
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
    Sallusto F; Lanzavecchia A
    J Exp Med; 1994 Apr; 179(4):1109-18. PubMed ID: 8145033
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Proliferating dendritic cell progenitors in human blood.
    Romani N; Gruner S; Brang D; Kämpgen E; Lenz A; Trockenbacher B; Konwalinka G; Fritsch PO; Steinman RM; Schuler G
    J Exp Med; 1994 Jul; 180(1):83-93. PubMed ID: 8006603
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Mechanisms of HIV/SIV mucosal transmission.
    Milman G; Sharma O
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1305-12. PubMed ID: 7848686
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells.
    Pope M; Gezelter S; Gallo N; Hoffman L; Steinman RM
    J Exp Med; 1995 Dec; 182(6):2045-56. PubMed ID: 7500050
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A highly reliable, sensitive, flow cytometric/fluorometric assay for the evaluation of the anti-HIV activity of antiviral compounds in MT-4 cells.
    Schols D; Pauwels R; Vanlangendonck F; Balzarini J; De Clercq E
    J Immunol Methods; 1988 Nov; 114(1-2):27-32. PubMed ID: 2903196
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.
    Van Herrewege Y; Vanham G; Michiels J; Fransen K; Kestens L; Andries K; Janssen P; Lewi P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3684-9. PubMed ID: 15388420
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.
    Huang B; Kang D; Yang J; Zhan P; Liu X
    Expert Opin Ther Pat; 2016; 26(2):281-9. PubMed ID: 26559996
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 5.